26 March 2015 : Original article
Preconditioning by Cilostazol Protects against Cold Hepatic Ischemia-Reperfusion Injury
Maximilian von HeesenABCDEF, Simon MüllerBC, Ulrich KepplerBE, Moritz J. StrowitzkiBE, Claudia ScheuerC, Martin K. SchillingADG, Michael D. MengerADEF, Mohammed R. MoussavianACDGDOI: 10.12659/AOT.893031
Ann Transplant 2015; 20:160-168
Abstract
BACKGROUND: In liver transplantation, prolonged cold storage and post-transplant reperfusion are associated with endothelial inflammation, organ dysfunction, and graft failure. We herein studied whether cilostazol, a phosphodiesterase-3-inhibitor, attenuates post-ischemic liver injury after prolonged cold storage.
MATERIAL AND METHODS: Sprague-Dawley rats were assigned to 5 groups (n=6 each): sham animals (cold storage time (CST): 1 h), vehicle-treated (NaCl 0.9%) controls (CST: 24 h), and animals receiving 0.1, 1.0, or 10.0 mg/kg body weight (BW) cilostazol pre-treatment (CST: 24 h). After organ explantation, all livers were stored at 4°C in HTK solution, followed by 60 min of reperfusion with 37°C Krebs Henseleit buffer in a non-recirculating ex situ system. Bile flow was measured to evaluate liver function. To analyze inflammation and morphology, liver tissue samples were taken and histology, immunohistochemistry, and Western blotting were conducted.
RESULTS: In vehicle-treated controls, prolonged cold storage and warm reperfusion induced inflammation, organ dysfunction, and cell death. This was indicated by an increase of hepatocellular vacuolization, endothelial ICAM-1 expression, and apoptotic cell death compared to sham animals. Cilostazol pre-treatment protected against cold hepatic ischemia-reperfusion injury by preventing hepatocellular disintegration, ICAM-1-associated endothelial inflammation, and apoptotic death.
CONCLUSIONS: Inhibition of PDE3 reduces endothelial cell activation and hepatocellular injury in cold ischemia/reperfusion of the liver.
Keywords: Cyclic AMP, Microcirculation, Organ Preservation
In Press
Case report
Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case SeriesAnn Transplant In Press; DOI: 10.12659/AOT.951715
Original article
Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952251
Original article
The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...Ann Transplant In Press; DOI: 10.12659/AOT.952031
Original article
Decreased Ventilation Duration and ICU Stay Associated With Early Percutaneous Dilatational Tracheostomy Af...Ann Transplant In Press; DOI: 10.12659/AOT.953143
Most Viewed Current Articles
24 Aug 2021 : Review article 20,545
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 16,641
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
05 Apr 2022 : Original article 15,898
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 15,796
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988






